The basophil proteome in chronic spontaneous urticaria distinguishes responders to omalizumab from non-responders

Clin Exp Allergy. 2018 Jul;48(7):898-901. doi: 10.1111/cea.13149. Epub 2018 May 20.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Allergic Agents / pharmacology*
  • Anti-Allergic Agents / therapeutic use
  • Basophils / immunology*
  • Basophils / metabolism*
  • Biomarkers
  • Case-Control Studies
  • Chronic Disease
  • Humans
  • Omalizumab / pharmacology*
  • Omalizumab / therapeutic use
  • Proteome*
  • Proteomics / methods
  • Urticaria / etiology*
  • Urticaria / metabolism*

Substances

  • Anti-Allergic Agents
  • Biomarkers
  • Proteome
  • Omalizumab

Associated data

  • ClinicalTrials.gov/NCT01701583